D-1544-2022 Class III Terminated

Recalled by QuVa Pharma, Inc. — Bloomsbury, NJ

FDA drug recall D-1544-2022 was initiated by QuVa Pharma, Inc. on Sep 20, 2022 and is designated Class III. Reason for recall: Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL). The recall status is terminated (terminated Feb 8, 2023). Affected quantity: 1994 bags.

Recall details

Product Type
Drugs
Report Date
Oct 5, 2022
Initiation Date
Sep 20, 2022
Termination Date
Feb 8, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1994 bags

Product description

oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injection for IV Use, High Alert, This is a Compounded Product for Institutional or Office Use Only, Not for Resale, QuVa PHARMA 519 Route 173, Bloomsbury, NJ 08804, Total volume: 500 mL bag, NDC: 70092-1068-07.

Reason for recall

Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).

Distribution pattern

Nationwide in the USA

Code information

Lot 30027403, BUD 11/14/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1544-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1544-2022. Report a data issue: hello@regdatalab.com.